CASE REPORT | STOMACH

# *Cytomegalovirus*-Related Gastritis in an Immunocompetent Host Presenting With Infectious Gastroparesis

ACG

Sonia Solito, MD, PhD<sup>1</sup>, Salvatore Francesco Vadalá di Prampero, MD, PhD<sup>2,3</sup>, Milutin Bulajic, MD, PhD<sup>2,3</sup>, Serena Battista, MD<sup>4</sup>, Giulia Tomassini, MD<sup>2</sup>, Nikola Panic, MD, PhD<sup>5</sup>, Katarina Jankovic, MD<sup>6</sup>, and Marco Marino, MD<sup>1</sup>

<sup>1</sup>Gastroenterology and GI Endoscopy Unit, Academic Medical Center of Udine, Udine, Italy
<sup>2</sup>Gastroenterology and GI Endoscopy Unit, Mater Olbia Hospital, Qatar Foundation Endowment & Gemelli Foundation, Olbia, Italy
<sup>3</sup>Department for Digestive Endoscopy, Ospedale Isola Tiberina – Gemelli Isola, Rome, Italy
<sup>4</sup>Department of Pathology, Academic Medical Center of Udine, Udine, Italy
<sup>5</sup>GI Endoscopy Unit, University Clinic "Dr Dragisa Misovic - Dedinje", Belgrade, Serbia
<sup>6</sup>Clinic for Gastroenterohepatology, University Clinical Centre of Belgrade, Belgrade, Serbia

## ABSTRACT

*Cytomegalovirus* (CMV) infection is usually asymptomatic or causes a mild mononucleosis-like syndrome, whereas severe symptoms are rarely reported. We report a case of a 70-year-old woman who was admitted to our center because of severe clinical presentation with anorexia, epigastric pain, nausea, postprandial vomiting, and significant weight loss. Esophagogastroduodeno-scopy with biopsies showed ulcerative chronic gastritis with scattered large cells with inclusion bodies. Immunohistochemistry and polymerase chain reaction for CMV-DNA resulted positive. A gastric emptying of solid scintigraphy showed severe gastroparesis. The patient was discharged after 2 months of antiviral therapy completely asymptomatic. To the best of our knowledge, this is the first case of CMV-related gastroparesis in an immunocompetent patient, successfully treated with antiviral therapy.

KEYWORDS: Cytomegalovirus (CMV); gastritis; gastroparesis; immunocompetent

## INTRODUCTION

*Cytomegalovirus* (CMV) is the member of the Herpesviridae family with a serology prevalence ranging from 45% to 100% worldwide.<sup>1</sup> The primary infection commonly occurs in childhood or early adolescence. After the acute infection, CMV remains silent, keeping its ability to reactivate in case of host's impaired immune function. The infection is usually asymptomatic or causes a mild mononucleosis-like syndrome,<sup>2</sup> whereas in immunocompromised patients, a severe and life-threatening disease may occur. Gastrointestinal disease associated with CMV infection can involve the entire alimentary tract,<sup>3</sup> and a minority of patients may develop an autonomic neuropathy with gastroparesis.<sup>4</sup> Antiviral therapy is recommended for severe infections in immunocompromised patients, whereas treatment in immunocompetent individuals is still debated.<sup>3,5,6</sup>

# CASE REPORT

A 70-year-old White woman was admitted to our Academic Medical Center for anorexia, epigastric pain, dyspepsia, nausea, postprandial vomiting, and weight loss (20 kg) in the past 3 months. Her medical history included essential hypertension, mitral valve prolapse, and surgically treated pulmonary cyst.

The initial esophagogastroduodenoscopy showed a granular mucosa and white spots in the gastric body and fundus, with histological examination resulting in chronic *Helicobacter pylori*-negative gastritis with scattered eosinophils in the lamina propria. Because

ACG Case Rep J 2023;10:e01231. doi:10.14309/crj.000000000001231. Published online: December 15, 2023 Correspondence: Katarina Jankovic, MD (kayajan91@gmail.com).



Figure 1. Endoscopic appearance of the gastric body.

nausea and vomiting did not improve, despite intravenous antiemetics and exclusion of medications potentially responsible for emesis, the patient was hospitalized and parenteral nutrition was started.

The transabdominal ultrasound was normal, and colonoscopy showed sigmoid diverticulosis. Laboratory tests revealed pancytopenia and elevated C-reactive protein (23.60 mg/L, reference range 0–5). Serology for *Brucella, Coxiella burnetii, Leptospira,* hepatitis B and C, human immunodeficiency virus, and stool *Clostridioides difficile* toxin assay was all negative. Rheumatic diseases, malignancy, lymphoma, and immune disorders were excluded. A positron emission tomography showed an abnormal tracer concentration in the stomach and in the first portion of the duodenum as a result of an acute inflammation. Repeat esophagogastroduodenoscopy (Figures 1 and 2) and small bowel enteroscopy revealed a congested mucosa with discrete ulcerative lesions with and without exudate, mainly in the antrum and distal gastric body, whereas erythema was found in the proximal and the



Figure 2. Endoscopic appearance of the gastric antrum.



**Figure 3.** Histological findings, representative image of the inclusion by *Cytomegalovirus*, called "owl's" eye in standard hematoxylin and eosin staining (20× field).

middle portion of the gastric body and duodenal bulb. Histology was consistent with severe ulcerative chronic gastritis, duodenitis, and scattered large cells with inclusion bodies were observed, which was typical for CMV-related infection (Figure 3). Immunohistochemistry using monoclonal CMV antibodies (Figure 4) and polymerase chain reaction (PCR) for CMV-DNA in plasma was positive (28,278 IU/mL). A gastric emptying of solid scintigraphy showed a severe gastroparesis with a half gastric emptying time of 155 minutes. The patient was started with intravenous ganciclovir 5 mg/kg twice daily, and prompt improvement of symptoms and pancytopenia in a few days was noted. Because pancytopenia was worsening again requiring white blood cell growth factors and platelet transfusion, ganciclovir was discontinued. A month later, EGD showed significant improvements of the mucosal injury (Figure 5). However, the histological examination detected a subatrophic chronic CMV-positive gastritis



**Figure 4.** Immunohistochemistry findings, representative image of the inclusion by *Cytomegalovirus*, with immunohistochemical staining (20× field).



**Figure 5.** Endoscopic appearance of the gastric antrum 2 months after the antiviral therapy.

with PCR for plasma CMV-DNA still positive (19,108 IU/mL). Considering the persistent CMV infection, oral valganciclovir 450 mg twice daily was started for 2 cycles of 3 weeks each until PCR test was negative. A second gastric emptying of solid scintigraphy was performed showing regular gastric emptying. The patient was discharged after 2 months completely asymptomatic without residual feeding issues.

## DISCUSSION

Gastrointestinal disease associated with CMV infection can involve the entire alimentary tract,<sup>3</sup> with colitis<sup>7</sup> and esophagitis<sup>8</sup> being the most common clinical manifestations. A minority of patients may develop an autonomic neuropathy, including gastroparesis that usually improves in a year, but sometimes, symptoms can persist for years with a worse prognosis.<sup>4</sup> We report a rare case of CMV

			-		-	-		
Study	Age (y)	Sex	History	Symptoms	Endoscopic findings	Histological findings	Treatment	Follow-up endoscopy
Crespo et al <sup>9</sup>	31	Μ	None	Epigastric pain and fever	Superficial erosions of the gastric antrum	Inclusion bodies and positive IHC staining	IV ganciclovir 5 mg/kg twice daily for 7 d	Full resolution, time of repeated endoscopy is not mentioned
Fyock et al <sup>10</sup>	83	Μ	Diabetes mellitus	Melena	Gastritis with multiple small antral, duodenal, and colonic ulcers	Inclusion bodies and positive IHC staining culture and PCR	21-day course of oral ganciclovir followed by IV administration	Partial healing of the duodenal ulcers after the antiviral therapy; full resolution 4 y later with the persistence of CMV
Ebisutani et al <sup>11</sup>	33	Μ	None	Epigastric pain, low- grade fever, and cough	Multiple gastric papules and a large irregularly shaped shallow ulcer	Positive IHC staining in the absence of inclusion bodies	Oral PPI (rabeprazole, 20 mg/day)	Small gastric ulcer on day 40; a residual ulce scar on day 68
Matsui et al <sup>12</sup>	29	Μ	N/A	Epigastric pain and fever	Multiple shallow gastric ulcers and mucosal erosions	Positive PCR for CMV- DNA in the absence of inclusion bodies	Oral PPI	Full resolution 2 mo later
Himoto et al <sup>13</sup>	31	Μ	None	Epigastric pain and fever	Multiple shallow gastric ulcers and mucosal edema	Inclusion bodies and positive IHC staining	Oral PPI (lansoprazole, 30 mg/day)	Full resolution 2 mo later
Xiong et al <sup>14</sup>	44	Μ	None	Epigastric pain and abdominal distention	Multiple erosions in the gastric antrum and thickening of the stomach wall	Inclusion bodies and positive IHC staining negative PCR for CMV- DNA	IV ganciclovir for 3 mo	Full resolution 3 mo later
Yamamoto et al <sup>15</sup>	35	Μ	None	Infectious mononucleosis syndrome	Thickened and eroded mucosa throughout the stomach	Positive IHC staining in the absence of inclusion bodies	None	Improvement, time of repeated endoscopy is not mentioned
Beany and Rainis <sup>16</sup>	66	Μ	None	Nausea, vomiting, weakness, night sweats, anorexia, and diarrhea	Large, irregularly shaped, deep ulcer in the gastric antrum and mucosal gastric erosions	Inclusion bodies and positive IHC staining positive PCR for CMV- DNA	Oral PPI (esomeprazole 40 mg/day)	Full resolution 2 mo later
Current report	70	F	Hypertension	Anorexia, epigastric pain, dyspepsia, nausea, postprandial vomiting, and weight loss	Gastric congestion and mucosal erosions	Inclusion bodies and positive IHC staining positive PCR for CMV- DNA	IV ganciclovir 5 mg/kg twice daily for 7 d + oral valganciclovir 450 mg twice daily for 2 cycles of 3 weeks each	Full resolution 2 mo later

	<i></i>		<b>~</b> · · · · ·	
Ishle I Sumn	mary of the nubliched data tro	m province cacae at aastric	Tytomogolovirus disposo ir	immunocompetent patients
I ADIC I. JUIIII				

CMV, Cytomegalovirus; EGD, esophagogastroduodenoscopy; IHC, immunohistochemistry; IV, intravenous; PCR, polymerase chain reaction; PPI, proton pump inhibitors.

gastritis with associated gastroparesis in an immunocompetent patient.

After PubMed research for case reports up to September 2023 (keywords: *Cytomegalovirus* AND immunocompetent AND gastric ulcer OR gastritis), of the 26 search results, we found 8 English articles on CMV gastric disease in immunocompetent adults eligible for inclusion (Table 1). Unlike to the case we report, all patients were male,  $^{9-16}$  and most of them were young adults with no underlying diseases. Similar to our case, CMV infection of the upper GI tract in immunocompetent hosts has been reported to cause multiple gastric erosions and ulcers similar to *H. pylori*– and nonsteroidal anti-inflammatory drugs-related ulcers.<sup>13</sup>

In a systematic review, Rafailidis et al<sup>3</sup> reported 290 cases of severe CMV infection in immunocompetent adults concluding that the incidence of severe manifestations of CMV infection in immunocompetent individuals may not be as rare as previously believed. CMV infection is generally treated with inhibitors of viral DNA polymerase such as ganciclovir or foscarnet, which may have many side effects (eg, nephrotoxicity, myelotoxicity, neurotoxicity, and hepatotoxicity); thus, their use is usually recommended for immunocompromised patients.<sup>3,5,10</sup> Immunocompetent individuals often do not need antiviral treatment; however, in case of severe clinical manifestations, they have been considered by some authors who reported favorable results in terms of clinical improvement.<sup>5,17-19</sup>

A meta-analysis of CMV colitis in immunocompetent hosts<sup>20</sup> showed that mortality rate was higher in males, patients with chronic diseases, and older than 55 years. Based on this, they suggested the use of antiviral therapy in these patient groups rather than in immunocompromised ones. Therefore, current data suggest antiviral therapy as appropriate for severe CMV disease in immunocompetent hosts.

*Cytomegalovirus* infection may present with severe gastritis and gastroparesis; therefore, endoscopy with biopsies is crucial diagnostic method as it was in this case. The antiviral therapy should be considered even in immunocompetent patients balancing the benefit/risk ratio case by case.

### DISCLOSURES

Authors contributions: S. Solito, S. Battista, and M. Marino were directly responsible for the patient and managed the whole clinical case. S. Solito, G. Tomassini, M. Bulajic, N. Panic, K. Jankovic, and SF Vadalá di Prampero were major contributors in writing of the manuscript, and all authors read and approved the final manuscript.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received September 14, 2023; Accepted November 14, 2023

#### REFERENCES

- 1. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol* 2010;20(4):202–13.
- Al-Omari A, Aljamaan F, Alhazzani W, Salih S, Arabi Y. Cytomegalovirus infection in immunocompetent critically ill adults: Literature review. *Ann Intensive Care* 2016;6(1):110.
- Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review. *Virol J* 2008;5:47.
- Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of Gastroenterology Clinical Guideline: Management of gastroparesis. *Am J Gastroenterol* 2013;108(1):18–37; quiz 38.
- Eddleston M, Peacock S, Juniper M, Warrell DA. Severe cytomegalovirus infection in immunocompetent patients. *Clin Infect Dis* 1997;24(1):52–6.
- Jain M, Duggal S, Chugh TD. Cytomegalovirus infection in nonimmunosuppressed critically ill patients. J Infect Dev Ctries 2011;5(8):571–9.
- Siegal DS, Hamid N, Cunha BA. Cytomegalovirus colitis mimicking ischemic colitis in an immunocompetent host. *Heart Lung J Crit Care* 2005;34(4):291–4.
- Venkataramani A, Schlueter AJ, Spech TJ, Greenberg E. Cytomegalovirus esophagitis in an immunocompetent host. *Gastrointest Endosc* 1994;40(3):392–3.
- Crespo P, Dias N, Marques N, Saraiva da Cunha J. Gastritis as a manifestation of primary CMV infection in an immunocompetent host. *BMJ case Rep* 2015;2015:bcr2014206991.
- Fyock C, Gaitanis M, Gao J, Resnick M, Shah S. Gastrointestinal CMV in an elderly, immunocompetent patient. R Med J 2014;97(6):53–6.
- 11. Ebisutani C, Kawamura A, Shibata N, et al Gastric ulcer associated with cytomegalovirus in an immunocompetent patient: Method for diagnosis. *Case Rep Gastroenterol* 2012;6(2):365–8.
- Matsui Y, Sugino N, Kaneko H, Watanabe M, Miura Y, Tsudo M. CMV quantitative PCR in the diagnosis of CMV-associated AGML in an immunocompetent host. *Intern Med* 2010;49(12):1265–7; author reply 1269.
- Himoto T, Goda F, Okuyama H, et al Cytomegalovirus-associated acute gastric mucosal lesion in an immunocompetent host. *Intern Med* 2009; 48(17):1521-4.
- Xiong X, Liu F, Zhao W, et al Cytomegalovirus infective gastritis in an immunocompetent host misdiagnosed as malignancy on upper gastrointestinal endoscopy: A case report and review of literature. *Hum Pathol* 2019; 92:107–12.
- Yamamoto S, Sakai Y. Acute gastritis caused by concurrent infection with Epstein–Barr virus and cytomegalovirus in an immunocompetent adult. *Clin J Gastroenterol* 2019;12(3):274–8.
- Beany A, Rainis T. CMV-related gastric ulcer and gastroduodenitis in an immunocompetent patient: A case report and literature review. *Case Rep Gastrointest Med* 2021;2021:3513223.
- Grilli E, Galati V, Bordi L, Taglietti F, Petrosillo N. Cytomegalovirus pneumonia in immunocompetent host: Case report and literature review. *J Clin Virol* 2012;55(4):356–9.
- Snape SE, Venkatesan P. Valganciclovir treatment of primary cytomegalovirus pneumonitis in an immunocompetent adult. *BMJ Case Rep* 2011; 2011:bcr1120103489.
- Serna-Higuera C, González-García M, Milicua JM, Muñoz V. Acute cholestatic hepatitis by cytomegalovirus in an immunocompetent patient resolved with ganciclovir. J Clin Gastroenterol 1999;29(3):276–7.
- Galiatsatos P, Shrier I, Lamoureux E, Szilagyi A. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. *Dig Dis Sci* 2005;50(4):609–16.

**Copyright:** © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.